Table 2.
Baseline characteristics of GBC patients after curative-intent resection.
| Variables | TO | χ2/Z | P value | Variables | TO | χ 2/Z | P value | ||
|---|---|---|---|---|---|---|---|---|---|
| No (n = 317) | Yes (n = 223) | No (n = 317) | Yes (n = 223) | ||||||
| Sex | 0.444* | 0.505 | Hybrid type | 25 (7.9) | 37 (16.6) | ||||
| Male | 98 (30.9) | 75 (33.6) | Pathological type of tumor | 0.377* | 0.539 | ||||
| Female | 219 (69.1) | 148 (66.4) | |||||||
| Age (years) | 5.631* | 0.018 | Adenocarcinoma | 249 (78.5) | 180 (80.7) | ||||
| ≤60 | 98 (30.9) | 91 (40.8) | Non-adenocarcinoma | 68 (21.5) | 43 (19.3) | ||||
| >60 | 219 (69.1) | 132 (59.2) | |||||||
| CEA (ng/mL) | 7.678* | 0.006 | Tumor differentiation | –4.666† | <0.001 | ||||
| ≤5.0 | 229 (72.2) | 184 (82.5) | Well | 32 (10.1) | 45 (20.2) | ||||
| >5.0 | 88 (27.8) | 39 (17.5) | Moderate | 137 (43.2) | 114 (51.1) | ||||
| CA19-9 (U/mL) | 22.723* | <0.001 | Poor | 148 (46.7) | 64 (28.7) | ||||
| ≤39.0 | 185 (58.4) | 174 (78.0) | Liver involvement | 40.091* | <0.001 | ||||
| >39.0 | 132 (41.6) | 49 (22.0) | No | 181 (57.1) | 185 (83.0) | ||||
| CA125 (U/mL) | 6.317* | 0.012 | Yes | 136 (42.9) | 38 (17.0) | ||||
| ≤35.0 | 213 (67.2) | 172 (77.1) | Major vascular invasion | 18.884* | <0.001 | ||||
| >35.0 | 104 (32.8) | 51 (22.9) | |||||||
| TBIL (μmol/L) | 23.729* | <0.001 | No | 288 (90.9) | 222 (99.6) | ||||
| ≤34.1 | 260 (82.0) | 214 (96.0) | Yes | 29 (9.1) | 1 (0.4) | ||||
| >34.1 | 57 (18.0) | 9 (4.0) | Perineural invasion | 3.942* | 0.047 | ||||
| Unexpected GBC | 21.631* | <0.001 | No | 274 (86.4) | 205 (91.9) | ||||
| No | 249 (78.5) | 134 (60.1) | Yes | 43 (13.6) | 18 (8.1) | ||||
| Yes | 68 (21.5) | 89 (39.9) | Microvascular invasion | 0.281* | 0.596 | ||||
| Gallstones | 1.402* | 0.236 | No | 298 (94.0) | 212 (95.1) | ||||
| No | 119 (37.5) | 95 (42.6) | Yes | 19 (6.0) | 11 (4.9) | ||||
| Yes | 198 (62.5) | 128 (57.4) | AJCC 8th edition T stage | –5.374† | <0.001 | ||||
| Gallbladder polyps | 8.121* | 0.004 | |||||||
| No | 304 (95.9) | 200 (89.7) | |||||||
| T1–2 | 43 (13.6) | 54 (24.2) | |||||||
| Yes | 13 (4.1) | 23 (10.3) | T3 | 227 (71.6) | 167 (74.9) | ||||
| 1.374* | 0.241 | ||||||||
| Lymph node dissection | T4 | 47 (14.8) | 2 (0.9) | ||||||
| AJCC 8th edition N stage | –1.790† | 0.073 | |||||||
| <6 | 131 (41.3) | 81 (36.3) | |||||||
| ≥6 | 186 (58.7) | 142 (63.7) | N0 | 199 (62.8) | 157 (70.4) | ||||
| Tumor location | 3.895* | 0.143 | N1 | 83 (26.2) | 46 (20.6) | ||||
| Neck | 63 (19.9) | 30 (13.5) | N2 | 35 (11.0) | 20 (9.0) | ||||
| Body and bottom | 182 (57.4) | 141 (63.2) | AJCC 8th edition TNM stage | –4.614† | <0.001 | ||||
| All gallbladder | 72 (22.7) | 52 (23.3) | |||||||
| Tumor morphology | 13.706* | 0.001 | I–II | 39 (12.3) | 50 (22.4) | ||||
| Massive type | 99 (31.2) | 80 (35.9) | III | 204 (64.4) | 151 (67.7) | ||||
| Infiltrating type | 193 (60.9) | 106 (47.5) | IVA-B | 74 (23.3) | 22 (9.9) | ||||
Data are presented as n (%). *χ2 value; †Z value. AJCC: American Joint Committee on Cancer; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CEA: Carcinoembryonic antigen; CI: Confidence interval; GBC: Gallbladder carcinoma; TBIL: Total bilirubin; TO: Textbook outcome.